Hunan Jiudian Pharmaceutical Co Ltd - Asset Resilience Ratio
Hunan Jiudian Pharmaceutical Co Ltd (300705) has an Asset Resilience Ratio of 2.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Hunan Jiudian Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Hunan Jiudian Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Hunan Jiudian Pharmaceutical Co Ltd.
Liquid Assets Composition Over Time
This chart breaks down Hunan Jiudian Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Hunan Jiudian Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥120.05 Million | 2.91% |
| Total Liquid Assets | CN¥120.05 Million | 2.91% |
Asset Resilience Insights
- Limited Liquidity: Hunan Jiudian Pharmaceutical Co Ltd maintains only 2.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hunan Jiudian Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hunan Jiudian Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Hunan Jiudian Pharmaceutical Co Ltd (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Hunan Jiudian Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.01% | CN¥161.29 Million ≈ $23.60 Million |
CN¥4.02 Billion ≈ $588.08 Million |
-3.72pp |
| 2024-12-31 | 7.73% | CN¥260.71 Million ≈ $38.15 Million |
CN¥3.37 Billion ≈ $493.60 Million |
+4.58pp |
| 2023-12-31 | 3.14% | CN¥90.29 Million ≈ $13.21 Million |
CN¥2.87 Billion ≈ $420.15 Million |
-0.78pp |
| 2022-12-31 | 3.92% | CN¥90.26 Million ≈ $13.21 Million |
CN¥2.30 Billion ≈ $336.51 Million |
-1.82pp |
| 2021-12-31 | 5.75% | CN¥100.31 Million ≈ $14.68 Million |
CN¥1.75 Billion ≈ $255.38 Million |
-- |
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches,… Read more